San Diego, CA -- (SBWire) -- 06/25/2010 -- Hanjo Hennemann, CEO/CSO at Nexigen GmbH, to speak at GTCbio’s 5th Assay and Drug Discovery Technologies on Sept. 20-21, 2010 in San Diego, CA.

Hanjo Hennemann will give a presentation on “Intracellular peptides: novel modulators for drug discovery and high content target validation.” at 5th Assay and Drug Discovery Technologies Conference to be held this year in San Diego, CA Sept. 20-21, 2010 by GTCbio. In this presentation, one will learn about the modulation of non-enzymatic target proteins by intracellular peptides, hear why intracellular peptide drugs are a validated alternative to siRNA-therapeutics, learn about novel peptide discovery technologies, and hear why intracellular peptides are excellent target validation tools, which are drug-like and generate high content data.

5th Assay and Drug Discovery Technologies Conference features a mixture of academic, industry and public sector experts in an intimate setting that favors the showcase of data, the exchanges of ideas and networking. Professionals in the drug discovery industry and academics to can get an update of exciting new developments in assay technologies and exchange ideas in developing creative approaches in the drug discovery and development process to improve the efficiency and output. For more information, visit http://www.gtcbio.com.